Polaryx Therapeutics (PLYX) EBITDA (2025 - 2026)
Polaryx Therapeutics' (PLYX) quarterly EBITDA came in at -$1.4 million in Q2 2026, down 56.11% year-over-year from -$3.1 million in Q2 2025, and up 29.52% quarter-over-quarter from -$2.0 million in Q1 2026.
Powered by 
Analysis
Polaryx Therapeutics (PLYX) EBITDA (2025 - 2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported EBITDA for 2 consecutive years, with -$1.4 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBITDA fell 56.11% year-over-year to -$1.4 million in Q2 2026; TTM through Jun 2026 was -$9.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$7.8 million, down 79.71% from the prior year.
- EBITDA was -$1.4 million for Q2 2026 at Polaryx Therapeutics, up from -$2.0 million in the prior quarter.
- Over five years, EBITDA peaked at -$884000.0 in Q2 2025 and troughed at -$5.1 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.01 Bn | 193.02 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 179.98 Bn | 176.80 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.02 Bn | 74.03 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 60.35 Bn | 55.16 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 53.69 Bn | 48.55 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.11 Bn | 29.80 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 29.21 Bn | 29.21 Bn | 1.16 Mn | -365.99 Mn |
| 10 | Polaryx Therapeutics | 97.52 Mn | 85.98 Mn | - | -1.38 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.38 Mn |
| Mar 31, 2026 | -1.96 Mn |
| Jun 30, 2025 | -884,000.00 |
| Mar 31, 2025 | -5.05 Mn |